Lamivudine (3tc) - Pharma

Relevant Publications

Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1.

Issue Release: 2024

Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.

Issue Release: 2024

Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.

Issue Release: 2024

Changes in blood lipid levels and influencing factors among treatment-naïve adult male HIV/AIDS patients following BIC/FTC/TAF vs. 3TC+EFV+TDF.

Issue Release: 2024

Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation.

Issue Release: 2024

Efficacy and safety of 2-drug regime dolutegravir/lamivudine in pregnancy and breastfeeding - clinical implications and perspectives.

Issue Release: 2024

Comprehensive Database of HIV Mutations Selected During Antiretroviral In Vitro Passage Experiments.

Issue Release: 2024

In depth analysis of the HIV reservoir confirms effectiveness and safety of DTG/3TC in a phase 4 randomized controlled switch trial (RUMBA).

Issue Release: 2024

A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1.

Issue Release: 2024

Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.

Issue Release: 2024

Exploring Co-Amorphous Formulations Of Nevirapine: Insights From Computational, Thermal, And Solubility Analyses.

Issue Release: 2024

Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial.

Issue Release: 2024

Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.

Issue Release: 2024

Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.

Issue Release: 2024

Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.

Issue Release: 2024

Clinical benefits of novel non-nucleoside reverse transcriptase inhibitors: A prospective cohort study.

Issue Release: 2024

Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.

Issue Release: 2024

DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain.

Issue Release: 2024

Comparison of safety and effectiveness of antiretroviral therapy regimens among pregnant women living with HIV at preconception or during pregnancy: a systematic review and network meta-analysis of randomized trials.

Issue Release: 2024

Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care.

Issue Release: 2024

How Can Pharma Companies Improve Patient Education?

What Are the Challenges of Clinical Trials?

What Causes Adverse Drug Events?

What are the Regulatory Requirements for Generic Drugs?

What Education and Training Do Pharmacists Need?

Why is Medication Management Important?

How Can Pharmacists Contribute to Transitional Care?

What is an Abbreviated New Drug Application (ANDA)?

How Do Collaborative Care Models Work?

Why is the Management of Chronic Conditions Important?

Lamivudine (3tc) - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics